![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
University of Cincinnati Novartis |
---|---|
Information provided by: | University of Cincinnati |
ClinicalTrials.gov Identifier: | NCT00594555 |
The purpose of this study is to evaluate the safety of combined chemotherapy treatment (CLAG regimen) with Imatinib Mesylate (Gleevec) in patients with AML.
Condition | Intervention | Phase |
---|---|---|
Chronic Myeloid Leukemia, Blast Crisis Acute Myeloid Leukemia |
Drug: Imatinib Mesylate Drug: CLAG |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Efficacy Study |
Official Title: | A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Acute Myeloid Leukemia |
Estimated Enrollment: | 20 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | November 2008 |
Estimated Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single Arm - treatment period: Experimental
Drug Name/Days Administered Neupogen/Days 1-6 CLAG/Days 2-6 Gleevec/Days 2-15 |
Drug: Imatinib Mesylate
Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
Drug: CLAG
Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2 Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2 G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days |
In relapsed or resistant acute myeloid leukemia (type of blood cancer where immature blood cells are increased, blocking normal blood cells production) no standard therapy exits. Response rates are similar for different chemotherapy treatments. Allogenic stem cell transplant remains the only curative option
The purpose of this study is to evaluate the safety of combined chemotherapy treatment (CLAG regimen) with Imatinib Mesylate (Gleevec). The CLAG regimen is a combination of the chemotherapy drugs cladribine and cytarabine, as well as, neupogen which increases the white blood counts.
Imatinib Mesylate is believed to work by interfering with the abnormal protein by blocking it from telling the body to keep making more and more abnormal white blood cells. Imatinib Mesylate is approved by the FDA for the treatment of chronic myeloid leukemia (CML) and some types of acute lymphoblastic leukemia (ALL). Its use in combination with CLAG regimen is considered experimental for the treatment of Acute Myeloid Leukemia / CML blast crisis
The goal of the study is to find out what effects (good and bad) Imatinib Mesylate (Gleevec)combined with chemotherapy (CLAG regimen) on acute myeloid leukemia.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Refractory or Relapsed AML.
Exclusion Criteria
United States, Ohio | |
University of Cincinnati | |
Cincinnati, Ohio, United States, 45267 |
Principal Investigator: | Rami S Komrokji, MD | The University of Cincinnati |
Responsible Party: | The University of Cincinnati ( Rami Komrokji, MD ) |
Study ID Numbers: | CST1571AU235 / Komrokji, CST1571AUS235 |
Study First Received: | January 3, 2008 |
Last Updated: | October 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00594555 |
Health Authority: | United States: Institutional Review Board |
Blood disease, bone marrow AML CML,Blast Crisis |
Cladribine Blast Crisis Chronic myelogenous leukemia Hematologic Diseases Myeloproliferative Disorders Acute myelogenous leukemia Leukemia, Myeloid |
Leukemia, Myeloid, Acute Imatinib Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Bone Marrow Diseases Acute myelocytic leukemia Cytarabine |
Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors Immunosuppressive Agents |
Protein Kinase Inhibitors Pharmacologic Actions Neoplasms Neoplastic Processes Pathologic Processes Therapeutic Uses Cell Transformation, Neoplastic |